Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code

WU Xue, LI Chuan-mei, QIAO Hua-min. The cost-effectiveness analysis of irbesartan and benazepril in treating primary hypertension[J]. Journal of Pharmaceutical Practice and Service, 2006, (2): 107-108.
Citation: WU Xue, LI Chuan-mei, QIAO Hua-min. The cost-effectiveness analysis of irbesartan and benazepril in treating primary hypertension[J]. Journal of Pharmaceutical Practice and Service, 2006, (2): 107-108.

The cost-effectiveness analysis of irbesartan and benazepril in treating primary hypertension

  • Received Date: 2005-08-26
  • Objective : To evaluate cost-effectiveness of irbesartan and benazepril in the treatment of primary hypertension. Methods : According to literatures and method of cost-effectiveness analysis, two drugs with the treatment of primary hypertension were eco-nomicaly evaluated. Results and Conclusion : There were no obvious difference between these two projects in treating primary hypertension.The cost of treatment of two drugs were 998.68 and 923.08 yuan.The cost-effectiveness ratio of benazepril is superior to that of irbesartan.
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Article Metrics

Article views(2359) PDF downloads(149) Cited by()

Related
Proportional views

The cost-effectiveness analysis of irbesartan and benazepril in treating primary hypertension

Abstract: Objective : To evaluate cost-effectiveness of irbesartan and benazepril in the treatment of primary hypertension. Methods : According to literatures and method of cost-effectiveness analysis, two drugs with the treatment of primary hypertension were eco-nomicaly evaluated. Results and Conclusion : There were no obvious difference between these two projects in treating primary hypertension.The cost of treatment of two drugs were 998.68 and 923.08 yuan.The cost-effectiveness ratio of benazepril is superior to that of irbesartan.

WU Xue, LI Chuan-mei, QIAO Hua-min. The cost-effectiveness analysis of irbesartan and benazepril in treating primary hypertension[J]. Journal of Pharmaceutical Practice and Service, 2006, (2): 107-108.
Citation: WU Xue, LI Chuan-mei, QIAO Hua-min. The cost-effectiveness analysis of irbesartan and benazepril in treating primary hypertension[J]. Journal of Pharmaceutical Practice and Service, 2006, (2): 107-108.

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return